Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Medicine type
Approval status
AllApproved in the United States (FDA)Approved in the European Union (EMA)In Phase 3 testingIn Phase 2 testingUsed in a way not covered by an approval, or made by a compounding pharmacyDietary supplement; not FDA-approved as a medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Laboratory or animal-stage researchControlled substance; no approved US useWithdrawn from the market
Amount of information
Showing 1–5 of 5 records
Exagamglogene autotemcel (Casgevy)
Gene-editing or gene therapyApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Sickle cell disease and transfusion-dependent beta-thalassemia
Lovotibeglogene autotemcel (Lyfgenia)
Gene-editing or gene therapyApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Sickle cell disease with a history of severe pain crises
Onasemnogene abeparvovec (Zolgensma)
Gene-editing or gene therapyApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Spinal muscular atrophy in babies under two
Voretigene neparvovec (Luxturna)
Gene-editing or gene therapyApproved in the United States (FDA)Detailed recordUse listed on the medicine record
An inherited form of childhood blindness caused by two faulty RPE65 genes
Etranacogene dezaparvovec (Hemgenix)
Gene-editing or gene therapyApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Haemophilia B in adults